Analysts Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Price Target at $6.22

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has received an average recommendation of “Buy” from the eight analysts that are presently covering the stock, MarketBeat.com reports. Eight research analysts have rated the stock with a buy rating. The average twelve-month price target among brokerages that have covered the stock in the last year is $6.38.

Several research analysts have commented on the stock. Piper Sandler decreased their price objective on shares of Taysha Gene Therapies from $9.00 to $7.00 and set an “overweight” rating for the company in a report on Monday, July 1st. Canaccord Genuity Group decreased their price target on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, August 14th. Chardan Capital restated a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, August 13th. Cantor Fitzgerald reiterated an “overweight” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Thursday, June 20th. Finally, JMP Securities restated a “market outperform” rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, June 20th.

Taysha Gene Therapies Stock Down 1.8 %

Shares of NASDAQ:TSHA opened at $2.15 on Tuesday. Taysha Gene Therapies has a 1 year low of $1.27 and a 1 year high of $4.32. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.22 and a quick ratio of 5.22. The stock’s 50-day moving average is $2.20 and its 200 day moving average is $2.59. The company has a market cap of $440.62 million, a PE ratio of -4.39 and a beta of 0.41.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its earnings results on Monday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. Taysha Gene Therapies had a negative return on equity of 168.91% and a negative net margin of 888.18%. The firm had revenue of $1.11 million for the quarter, compared to analysts’ expectations of $3.62 million. During the same period in the previous year, the firm earned ($0.38) earnings per share. Sell-side analysts anticipate that Taysha Gene Therapies will post -0.35 EPS for the current year.

Insider Transactions at Taysha Gene Therapies

In related news, major shareholder Paul B. Manning bought 1,333,333 shares of the company’s stock in a transaction on Thursday, June 27th. The shares were acquired at an average cost of $2.25 per share, with a total value of $2,999,999.25. Following the completion of the acquisition, the insider now owns 1,333,333 shares of the company’s stock, valued at approximately $2,999,999.25. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 2.70% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in TSHA. Victory Capital Management Inc. bought a new stake in shares of Taysha Gene Therapies during the fourth quarter valued at approximately $28,000. Dynamic Technology Lab Private Ltd purchased a new stake in Taysha Gene Therapies during the 4th quarter valued at $31,000. Avoro Capital Advisors LLC boosted its stake in Taysha Gene Therapies by 11.0% during the 4th quarter. Avoro Capital Advisors LLC now owns 4,355,555 shares of the company’s stock valued at $7,709,000 after purchasing an additional 430,555 shares during the last quarter. ADAR1 Capital Management LLC bought a new stake in shares of Taysha Gene Therapies in the 4th quarter worth $370,000. Finally, Chicago Partners Investment Group LLC raised its stake in shares of Taysha Gene Therapies by 21.4% in the fourth quarter. Chicago Partners Investment Group LLC now owns 134,851 shares of the company’s stock worth $239,000 after purchasing an additional 23,740 shares during the last quarter. Institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.